ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The pharmaceutical services firm Lonza has agreed to manufacture dovitinib, an investigational pan-tyrosine kinase inhibitor for metastatic renal cell carcinoma, for the Danish biotech firm Allarity Therapeutics. Under the contract, active ingredient production and particle reduction by micronization will take place at Lonza’s facility in Visp, Switzerland. Lonza will make the finished drug in Tampa, Florida. Novartis licensed dovitinib to Allarity in 2018 after disappointing trials as a kidney cancer drug.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter